Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.06. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VOOG | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $85.42 |
52-Week Low | $16.87 | $65.32 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $85.42, up 0.68% on the day and near a 52-week high. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI suggests overbought conditions. Recent news highlights institutional accumulation, such as Apella Capital increasing its stake by 463.2% in Q2 2026, and positive coverage from financial outlets comparing its low expense ratio and growth focus favorably against peers.
The outlook for VOOG remains positive, driven by exposure to large-cap growth stocks and strong institutional interest. Key risks include high concentration in technology sectors, making it vulnerable to sector-specific downturns, and broader market volatility. Its low expense ratio of 0.07% and historical outperformance present a compelling case for growth-oriented investors, but caution is warranted given elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
